For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251008:nRSH4597Ca&default-theme=true
RNS Number : 4597C Angle PLC 08 October 2025
8 October 2025
ANGLE plc ("the Company")
Appointment of Executive Chairman, proposed change of name and strategy update
Company to pursue revised strategy and name change to CelLBxHealth plc
Dr. Jan Groen, the current Non-Executive Chairman and recognised oncology
diagnostic industry veteran, to lead company as Executive Chairman
Revised strategy to sharpen focus on the provision of industry-leading CTC
intelligence and accelerate Company's commercial traction, whilst delivering
further cost control
Cash runway remains through to Q1 2026; expected need to raise funds in coming
months
ANGLE plc (AIM:AGL OTCQX:ANPCY), a global precision CTC intelligence company
specialising in innovative circulating tumour cell (CTC) solutions for use in
research, drug development and clinical oncology, announces that its
Chairman, Dr Jan Groen, has moved into an executive role. Jan will lead the
Company as it pursues a revised strategy, focused on tight cost control,
accelerated commercial progress and a clear plan towards becoming a
sustainable business.
Jan has over 25 years of experience in the commercialisation of clinical and
personalised oncology diagnostics, and has led the turnaround of several
companies, one of them being a publicly listed company, Oncomethylome Science,
that has continued successfully after its restructure as MDxHealth (NASDAQ:
MDXH). Jan is working alongside the senior management team to identify the
appropriate ongoing cost base whilst progressing a number of potential
collaborations and partnerships that were detailed in the interim results in
early September.
As part of its revised strategy, the Company proposes to change its name to
CelLBxHealth plc. The new name reflects the Company's sharpened focus on 'CTC
intelligence', the provision of high-value CTC-based precision diagnostic
testing for the pharmaceutical services sector and the clinical diagnostics
market.
The Board believes that the new name, CelLBxHealth, encapsulates the Company's
aspirations. "CelLBx" (short for Circulating Tumour Cells obtained via liquid
biopsy, "LBx") reflects a key and rapidly emerging field of healthcare
innovation, where diagnostics and therapeutics increasingly converge. The
addition of "Health" underscores the Company's core mission: to support
pharmaceutical companies and clinicians in improving outcomes for cancer
patients.
The initial emphasis will be on the proteomics and genomics market segment.
Here the Company will seek to maximise the potential of its proprietary
Parsortix platform for CTC isolation by developing applications that integrate
existing proteomics and genomic assays capable of providing complementary
insights to circulating tumour DNA.
The change of name is expected to take effect in mid-October, following the
issuance of a Certificate of Incorporation on change of name by Companies
House. The Company's AIM ticker will be CLBX.
As highlighted in the recent interim results statement, the Company has a cash
runway into Q1 2026. As such, the expectation is that the Company will need to
raise funds in the coming months. This process will commence once there is
clarity on the appropriate cost base, funding need and a clear path to greater
commercial traction.
Andrew Newland, Chief Executive, and Ian Griffiths, Finance Director have
continued to provide support to the Company in their non-board roles and will
be transitioning out of the business in due course. Their contractual
entitlements will be honoured over the next 12 months, with no acceleration of
these costs expected to affect the Company's cash runway.
For further information:
ANGLE plc +44 (0) 1483 343434
Dr Jan Groen, Executive Chairman investor@angleplc.com
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper (Corporate Finance) +44 (0) 20 7220 0500
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)
Notes for editors
About ANGLE plc
ANGLE plc is a global precision CTC intelligence company specialising in
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology. Its patent-protected Parsortix® platform
harvests CTCs from blood and enables comprehensive downstream analysis -
including whole-cell imaging, proteomic profiling and full genomic workflows -
supporting research, drug development and clinical oncology.
Commercial activities centre on (i) biopharma clinical services, (ii)
partnerships, (iii) development of laboratory-developed tests (LDTs), and (iv)
Research Use Only validation of existing commercial proteomic and genomic
assays. The product portfolio comprises the Parsortix® platform with
associated consumables and assays. Biopharma services are delivered from
ANGLE's GCLP-compliant UK laboratory, providing bespoke LDT development,
clinical-trial testing and service testing.
For more information, visit www.angleplc.com (http://www.angleplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDFFFLIIALDIIE